Sagimet Biosciences (SGMT) announced that Ascletis Pharma (ASCLF) issued a December 10 statement that China’s National Medical Products Administration, NMPA, has accepted its New Drug Application, NDA, for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience, of which Ascletis Pharma is the parent company.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position
- 3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts
- Sagimet Biosciences, Inc.: Promising Pipeline and Strong Financial Position Justify Buy Rating
- Sagimet Biosciences price target raised to $35 from $33 at Citizens JMP
- Sagimet Biosciences Reports Q3 2025 Financial Results